FibroGen Inc is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for anemia, fibrotic diseases, and chronic kidney disease
The organization focuses on the development of novel treatments that harness the body's natural processes to promote healthy red blood cell production and reduce fibrosis, thereby addressing significant unmet medical needs. Through its cutting-edge research and clinical trials, FibroGen aims to improve patient outcomes and enhance the quality of life for individuals suffering from these serious health conditions.
FibroGen reports topline results from late-stage trials of pamrevlumab for pancreatic cancer, failing to meet the primary endpoint of overall survival.
FibroGen Inc (NASDAQFGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial supply agreement with Regeneron.
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial supply agreement with Regeneron.
FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902 million which beat the analyst consensus estimate of $36.666 million by 52.46% and is a significant increase over sales of $36.161 million from the same period last year.
